A Study of LY3451838 in Healthy Participants

Phase 1 Completed 53 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindBasic science

Summary

The study has two parts. In Part A, single increasing doses of LY3451838 will be administered intravenously (into a vein). In Part B, a single dose of LY3451838 will be administered subcutaneously (just under the skin).

Timeline

Start: 2018-12-11
Primary completion: 2020-02-26
Completion: 2020-02-26

Publications

Johnson MP, Krikke-Workel J, Patel CN, Morin SM, Turner PK, Clark KA, Donley D, Jin Y, Johnson KW, Vincent M, Stille JR, Broad LM, Patel A. Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine. Cephalalgia. 2025 Aug;45(8):3331024251368757. doi: 10.1177/03331024251368757. Epub 2025 Aug 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VIPALANEBART	Monoclonal antibody	25 mg	Intravenous
Subject	VIPALANEBART	Monoclonal antibody	75 mg	Intravenous
Subject	VIPALANEBART	Monoclonal antibody	250 mg	Intravenous
Subject	VIPALANEBART	Monoclonal antibody	500 mg	Intravenous
Subject	VIPALANEBART	Monoclonal antibody	1000 mg	Intravenous
Subject	VIPALANEBART	Monoclonal antibody	1500 mg	Intravenous

Indications

No indication recorded.